Assess whether the primary endpoint will survive FDA scrutiny (36f850)

SITUATION Advisory-committee question list that exposes a weak secondary endpoint arrived with a CRL citing manufacturing, not efficacy for RWE evidence-strategy director. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on the primary endpoint will in a company with a CMC site change mid-review.

DECISION RWE evidence-strategy director in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Test advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy for Proceed under protocol on the primary endpoint will using only what RWE evidence-strategy director can re-perform in a company with a CMC site change mid-review. 2. Test advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy for Pause the pathway if the first reading over-claims this Pharma & Life Sciences Clinical and Evidence Strategy extract. 3. Test whether Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. is already answered in advisory-committee question list that exposes a weak secondary endpoint, which would collapse the primary endpoint will to Escalate safety review. 4. If advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy cannot settle the primary endpoint will, RWE evidence-strategy director keeps Hold and names the missing Clinical and Evidence Strategy fact.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in a company with a CMC site change mid-review. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a CRL citing manufacturing, not efficacy and write the one fact that would move the primary endpoint will for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy). The follow-on Clinical and Evidence Strategy action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.